Research Papers:

Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma

Min Fang, Tao Song, Xiaodong Liang, Shiliang Lv, Jianbo Li, Hong’en Xu, Limin Luo and Yongshi Jia _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:37080-37090. https://doi.org/10.18632/oncotarget.16180

Metrics: PDF 1920 views  |   HTML 2311 views  |   ?  


Min Fang1,*, Tao Song1,*, Xiaodong Liang1, Shiliang Lv1, Jianbo Li2, Hong’en Xu1, Limin Luo1, Yongshi Jia1

1Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, Hangzhou 310000, Zhejiang, P. R. China

2Department of Radiation Oncology, Ningbo Mingzhou Hospital, Ningbo 315000, Zhejiang, P. R. China

*These authors contributed equally to this work

Correspondence to:

Limin Luo, email: [email protected]

Yongshi Jia, email: [email protected]

Keywords: definitive concourrent chemoradiotherapy, esophageal squamous cell carcinoma, S-1, cisplatin, paclitaxel

Received: June 20, 2016     Accepted: March 03, 2017     Published: March 14, 2017


This study compared the efficiency and safety of definitive concurrent chemoradiotherapy (CCRT) using Paclitaxel plus Cisplatin (TP) versus S-1 plus Cisplatin (CS) in unresectable locally advanced esophageal squamous cell carcinoma (LAESCC). Between January 2009 and December 2013, 203 LAESCC patients were retrospectively reviewed. We performed a propensity score matching analysis; 41 patients treated with the CS regimen were matched 1:1 to patients who received the TP regimen. Patient- and disease-related characteristics were well-balanced between the two groups. The CS group showed significantly better treatment compliance (90.2% vs. 70.7%, P = 0.026) and less hospital stay (48 days vs 49 days, P = 0.025) over the TP group during the CCRT course. The complete response rate was comparable between the two groups (51.2% vs. 48.8%, P = 0.825). The 1- and 3-year overall survival (OS) rates in the TP group were 63.4% and 32.4% compared to 62.8% and 32.1% in the CS group, respectively (P = 0.796). The 1- and 3-year progression-free survival (PFS) rates in the TP group were 51.2% and 24.9%, compared to 53.6% and 18.9% in the CS group, respectively (P = 0.630). The incidence of severe and total neutropenia in the TP group was significantly higher compared to the CS group (P = 0.011 and 0.046, respectively). Multivariate analysis revealed that T stage and the complete response rate were strong prognostic factors associated with OS and PFS. In conclusion, both treatment regimens yielded satisfactory survival outcomes, but the CS regimen could significantly improve treatment compliance, reduce hematological toxicities and lengths of hospital stay. Future prospective studies in large cohorts are highly warranted to confirm the findings in our report.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16180